Literature DB >> 3581397

Comparison of atracurium and succinylcholine for electroconvulsive therapy in a patient with atypical plasma cholinesterase.

D R Hickey, J P O'Connor, F Donati.   

Abstract

Succinylcholine 2-5 mg or atracurium 10-15 mg were given on five separate occasions to a 24-year-old, 64 kg woman homozygous for atypical plasma cholinesterase who was undergoing electroconvulsive therapy (ECT). Atracurium blockade was reversed with atropine, 0.6 mg and edrophonium, 35 mg. Train-of-four stimulation was applied to the ulnar nerve and the force of contraction of the adductor pollicis muscle was recorded. Doses producing 90 per cent first twitch blockade were 2.5 and 15 mg for succinylcholine and atracurium respectively. The onset of action was 6 min for both relaxants, and time to 90 per cent first twitch recovery was 20 min for succinylcholine and 16 min for the atracurium-edrophonium combination. It is concluded that the use of atracurium in these patients does not offer marked advantages over small doses of succinylcholine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581397     DOI: 10.1007/bf03015165

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  13 in total

1.  Use of succinylcholine in the presence of atypical cholinesterase.

Authors:  S Lee-Son; R N Pilon; A Nahor; B E Waud
Journal:  Anesthesiology       Date:  1975-10       Impact factor: 7.892

Review 2.  Pharmacokinetics of the nondepolarizing neuromuscular relaxants applied to calculation of bolus and infusion dosage regimens.

Authors:  C A Shanks
Journal:  Anesthesiology       Date:  1986-01       Impact factor: 7.892

3.  Electroconvulsive therapy: physiological and anaesthetic considerations.

Authors:  R J Marks
Journal:  Can Anaesth Soc J       Date:  1984-09

4.  In vitro degradation of atracurium in human plasma.

Authors:  R A Merrett; C W Thompson; F W Webb
Journal:  Br J Anaesth       Date:  1983-01       Impact factor: 9.166

5.  Molecular weight of cation as a determinant of speed of onset of neuromuscular blockade.

Authors:  I M Ramzan
Journal:  Anesthesiology       Date:  1982-09       Impact factor: 7.892

Review 6.  Suxamethonium.

Authors:  N N Durant; R L Katz
Journal:  Br J Anaesth       Date:  1982-02       Impact factor: 9.166

Review 7.  Plasma cholinesterase variants and the anaesthetist.

Authors:  M Whittaker
Journal:  Anaesthesia       Date:  1980-02       Impact factor: 6.955

8.  Repeated administration of suxamethonium in a patient with atypical plasma cholinesterase.

Authors:  N M Cass; L A Doolan; G A Gutteridge
Journal:  Anaesth Intensive Care       Date:  1982-02       Impact factor: 1.669

Review 9.  Clinical pharmacology of vecuronium and atracurium.

Authors:  R D Miller; S M Rupp; D M Fisher; R Cronnelly; M R Fahey; Y J Sohn
Journal:  Anesthesiology       Date:  1984-10       Impact factor: 7.892

10.  Succinylcholine apnoea: attempted reversal with anticholinesterases.

Authors:  D R Bevan; F Donati
Journal:  Can Anaesth Soc J       Date:  1983-09
View more
  3 in total

Review 1.  Onset of action of relaxants.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

Review 2.  Anesthetic care for electroconvulsive therapy.

Authors:  Kyoung-Woon Joung; Dong Ho Park; Chang Young Jeong; Hong Seuk Yang
Journal:  Anesth Pain Med (Seoul)       Date:  2022-04-15

3.  Rocuronium and sugammadex: An alternative to succinylcholine for electro convulsive therapy in patients with suspected neuroleptic malignant syndrome.

Authors:  Karthik G Ramamoorthy; H Downey; P Hawthorne
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.